Madison Foster

Madison Foster

Auto-generated profile, based on publicly available information

Madison Foster

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2021 in PLOS Biology
Verified
Journal Article
Open access
PDF file
VHVictoria T. Hunniford
Victoria T. Hunniford
JMJoshua Montroy
Joshua Montroy
DFDean A. Fergusson
Dean A. Fergusson
MAMarc Avey
Marc Avey
KWKimberley E. Wever
Kimberley E. Wever
MLManoj M. Lalu
Manoj M. Lalu
In an effort to better utilize published evidence obtained from animal experiments, systematic reviews of preclinical studies are increasingly more common—along with the methods and tools to appraise them (e.g., SYstematic Review Center for Laboratory animal Experimentation [SYRCLE’s] risk of bias tool). We performed a cross-sectional study of a sample of recent preclinical systematic reviews (2015–2018) and examined a range of epidemiological characteristics and used a 46-item checklist to assess reporting details. We identified 442 reviews published across 43 countries in 23 different disease domains that used 26 animal species. Reporting of key details to ensure transparency and reproducibility was inconsistent across reviews and within article sections. Items were most completely reported in the title, introduction, and results sections of the reviews, while least reported in the methods and discussion sections. Less than half of reviews reported that a risk of bias assessment for internal and external validity was undertaken, and none reported methods for evaluating construct validity. Our results demonstrate that a considerable number of preclinical systematic reviews investigating diverse topics have been conducted; however, their quality of reporting is inconsistent. Our study provides the justification and evidence to inform the development of guidelines for conducting and reporting preclinical systematic reviews.

6 April 2022 in Cytotherapy
Verified
Journal Article
Open access
MFMadison Foster
Madison Foster
DFDean A. Fergusson
Dean A. Fergusson
VHVictoria Hunniford
Victoria Hunniford
ACAnalyssa Cardenas
Analyssa Cardenas
GCGisell Castillo
Gisell Castillo
MLManoj M. Lalu
Manoj M. Lalu
Early-phase cell therapy clinical trials depend on patient and physician involvement, yet barriers can impede their participation. To optimize engagement for a planned cell therapy trial to prevent perioperative cardiac complications, the authors conducted semi-structured interviews with at-risk patients and physicians who could potentially be involved in the study. The authors used the theoretical domains framework to systematically identify potential barriers and enablers. Forty-one interviews were conducted to reach data saturation, and four overall potential barriers to participation (themes) were identified. Theme 1 emphasizes that patients and physicians need accessible information to better understand the benefits and risks of the novel therapy and trial procedures and to address misconceptions. Theme 2 underscores the need for clarity on whether the trial's primary purpose is safety or efficacy, as this may influence patient and physician decisions. Theme 3 recognizes the resource and logistic realities for patients (e.g., convenient follow-up appointments) and physicians (e.g., personnel to assist in trial procedures, competing priorities). Theme 4 describes the importance of social influences (e.g., physicians and family, peers/colleagues) that may affect decisions to participate and the importance of patient preferences (e.g., availability of physicians to discuss the trial, including caregivers in discussions). Prospectively addressing these issues may help optimize feasibility prior to conducting an expensive, resource-intensive trial.